MINNEAPOLIS, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced that it will release its financial results for its third fiscal quarter ended September 30, 2025 on Wednesday, November 12, 2025, before the market opens. Vireo Growth management will host a conference call with the investment community that same day, Wednesday, November 12, 2025, at 8:30 a.m. ET (7:30 a.m. CT) to discuss its results. Interested parties may attend the confer ...

Core Insights - Corvus Pharmaceuticals, Inc. will engage with investors through one-on-one meetings and a fireside chat at the Guggenheim 2 Annual Healthcare Innovation Conference in Boston, MA on November 10, 2025 at 8:30 am ET [1] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel immunotherapy approach for various cancers and immune diseases [3] - The company's lead product candidate is soquelitinib, an investigational oral small molecule drug that selectively inhibits ITK [3] - Corvus has additional clinical-stage candidates targeting a range of cancer indications [3] Event Details - A live webcast of the fireside chat will be available, along with access for 90 days post-event, through the investor relations section of the Corvus website [2]

Delivered 6% Earnings Growth and Operating Ratio of 61.4%, an improvement of 170 basis points.Repurchased close to 8 million shares in the quarter for approximately C$1 billion.Improving productivity, including an additional C$75 million in labor cost reductions.Guiding to 2026 capital expenditures of C$2.8 billion*. (2) MONTREAL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) today reported its financial and operating results for the third quarter ended September 30, 2025. “I want to thank the ...

TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Northfield Capital Corporation (TSX-V: NFD.A) (or “Northfield”) and Juno Corp. (or “Juno”) welcome the announcement that Webequie First Nation and the Province of Ontario have signed a Community Partnership Agreement (the “Agreement”) to advance planning for the proposed Webequie Supply Road and priority community infrastructure investments. This milestone Agreement represents a transformational step forward in developing the critical infrastructure necessary to un ...

TDAQ exceeds $25M in AUM as TSPY hits new heights with $120M in AUMSEATTLE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TappAlpha, a fintech-powered ETF issuer focused on making advanced investment strategies accessible, is proud to announce that TDAQ, its actively managed income ETF built on the Nasdaq-100, has surpassed $25 million in assets under management (AUM) less than two months after launch. Since inception on September 4, 2025, TDAQ has delivered a total return of 10.57%, outperforming its underlying benchm ...

WILMINGTON, Del., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Acorn Energy, Inc. (Nasdaq: ACFN), a provider of remote monitoring and control solutions for backup power generators, gas pipelines and other industrial equipment, will report its third quarter and year-to-date results before the market opens on Thursday, November 6th and host a conference call at 11:00 a.m. ET. Jan Loeb, President & CEO, and Tracy Clifford, CFO & COO of OmniMetrix, will answer investor questions following prepared remarks. All investors a ...

Highlights New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose levelPositive data from ATH434-202 open-label trial demonstrates similar treatment effect in advanced MSA as observed in earlier stage patients in double-blind studyIndependent commercial assessment indicates USD $2.4 billion dollar potential worldwide peak sales opportunity in MSA for ATH434Cash balance on 30 September 2025 of A$54.56M MELBOURNE, Australia and SAN FRANCISCO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- A ...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, Canada, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Oroco Resource Corp. (TSX-V: OCO, OTCQB: ORRCF) confirms that the non-brokered private placement financing, announced on September 25, 2025, is proceeding as planned and will be completed within the necessary regulatory timeframe. The Offering is for up to 18,000,000 Units at a price of US$0.20 per Unit (for aggregate gross proceeds of up to US$3.6 million, with an an ...

Earnings Release: Tuesday, November 4, 2025, Before Market OpensConference Call and Webcast: Tuesday, November 4, at 8:30 a.m. ET MONACO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Costamare Inc. (NYSE:CMRE) (the “Company”), announced today that it will release its results for the third quarter ended September 30, 2025 before the market opens in New York on November 4, 2025. Conference Call Details: On Tuesday, November 4, 2025 at 8:30 a.m. ET, Costamare’s management team will hold a conference call to discuss the ...

Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA Patients randomized to either 10 or 20 mg/kg of muzastotug, in combination with KEYTRUDA with up to 30 patients per arm Company anticipates trial completion in early 2027, and potential updates in 2026 Additional updates from the ongoing Phase 1b/2 trial with muzastotug, previously reported at ASCO 2025, are anticipated in the coming months SAN DIEGO and SUZHOU, China, ...